Trial · NCT04493424
Adverse events46
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 46
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site erythema | General disorders | Spesolimab (BI 655130) | 20 | 108 | |
| other | Injection site induration | General disorders | Spesolimab (BI 655130) | 6 | 108 | |
| other | Injection site pain | General disorders | Spesolimab (BI 655130) | 9 | 108 | |
| other | Injection site pruritus | General disorders | Spesolimab (BI 655130) | 6 | 108 | |
| other | Injection site swelling | General disorders | Spesolimab (BI 655130) | 12 | 108 | |
| other | Injection site warmth | General disorders | Spesolimab (BI 655130) | 6 | 108 | |
| other | Pyrexia | General disorders | Spesolimab (BI 655130) | 14 | 108 | |
| other | COVID-19 | Infections and infestations | Spesolimab (BI 655130) | 30 | 108 | |
| other | Nasopharyngitis | Infections and infestations | Spesolimab (BI 655130) | 16 | 108 | |
| other | Upper respiratory tract infection | Infections and infestations | Spesolimab (BI 655130) | 6 | 108 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Spesolimab (BI 655130) | 12 | 108 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Spesolimab (BI 655130) | 11 | 108 | |
| other | Headache | Nervous system disorders | Spesolimab (BI 655130) | 8 | 108 | |
| other | Dermatitis contact | Skin and subcutaneous tissue disorders | Spesolimab (BI 655130) | 7 | 108 | |
| other | Eczema | Skin and subcutaneous tissue disorders | Spesolimab (BI 655130) | 9 | 108 | |
| other | Palmoplantar pustulosis | Skin and subcutaneous tissue disorders | Spesolimab (BI 655130) | 8 | 108 | |
| serious | Cardiac failure chronic | Cardiac disorders | Spesolimab (BI 655130) | 1 | 108 | |
| serious | Tricuspid valve incompetence | Cardiac disorders | Spesolimab (BI 655130) | 1 | 108 | |
| serious | Hypertrophic cardiomyopathy | Congenital, familial and genetic disorders | Spesolimab (BI 655130) | 1 | 108 | |
| serious | Colitis | Gastrointestinal disorders | Spesolimab (BI 655130) | 1 | 108 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04493424/events